Children with the novel coronavirus disease 2019 (COVID-19) may not develop a fever or cough as often as adults with the virus.
As COVID-19 continues to spread, and the death toll rises, experts aim to better understand the clinical features of the disease and factors for increased mortality.
The study will evaluate ruxolitinib (Jakavi) for the treatment of COVID-19-associated cytokine storm.
Nintedanib (Ofev, Boehringer Ingelheim Pharmaceuticals) has been approved for the treatment of chronic fibrosing interstitial lung disease with a progressive phenotype.
The FDA is requesting that manufacturers of bacitracin for injection voluntarily withdraw their product.
Data tracked by wearable fitness sensors may help with real-time surveillance of seasonal respiratory infections, such as influenza.
The 2019 Novel Coronavirus outbreak in Wuhan City, China has caused concern as 2 cases have been recently reported in the United States.
Lefamulin was approved by the FDA in August 2019 for the treatment of CABP.
Fewer tracheobronchial branches may be a genetically-related risk factor.